|
In a cohort of patients with ovarian cancer, tumor shrinkage was observed in 81% of patients, and stable disease was reported in 48% of patients. The overall week-12 illness control rate, or DCR, was 64%. Furthermore, in a subset analysis, the activity of XL184 in both platinum-sensitive and platinum-resistant/refractory cancer was also extremely promising. In a cohort of patients with prostate cancer, 95% of patients achieved complete or partial resolution of metastatic bone lesions. For soft tissue lesions, tumor shrinkage was observed in 69% of patients, and stable disease was reported in 74% of cases. The week-12 DCR in the prostate cancer cohort was 71%. No main safety issues had been observed in either trial.
|
